Investors & Partnering
Diabetes is s very serious disease both for the individual patient and as well as for society with enormous increases in world-wide health care spendings.
In PILA PHARMA, we believe that we have discovered a new treatment that can delay or maybe even stop this pandemic – and we feel obliged to explore this.
Development of novel drugs is a lengthy and costly process with a high risk of failure but with a potential to “do good while doing well”.
Are you the new PILA PHARMA investor?
PILA PHARMAs forsees 2-3 more investment rounds prior to exit to finance the pivotal efficacy trials of XEN-D0501 in type 2 diabetics patients.
If your are interested in becoming an investor in PILA PHARMA, please, contact us for more information here.
Are you the new PILA PHARMA friend ?
PILA PHARMA is a young virtual company with limited ressources and a worthy goal of trying to limit the consequences of diabetes – we believe in “the power of people” and we therefore welcome volunteers. We accept cost-free contributions of relevant knowledge and expertise, general support as well as financial donations.
Please, contact us for more information here.
Are you the new PILA PHARMA partner ?
Diabetes is a complex disease and the development, registration and marketing of novel diabetes drugs requires special talent, know-how and financial muscles.
PILA PHARMA’s aim is to mature XEN-D0501 as novel oral anti-diabetic agent to a stage where it becomes attractive for partnering with the right party.
If we didn’t yet talk to you or if you wish more information, please contact us here.
Current investors in PILA
PILA PHARMA is founded and partially owned by XENIA PHARMA, Denmark. Further, ALMI Invest, Sweden has invested twice, ALMI Företagspartner, Sweden has awarded an innovation loan and from June 2016 private investors have joined the group of PILA PHARMA investors.
ALMI Invest and ALMI Företagsparter provides consultancy, investment and loans to Swedish companies with scalable business concepts and prospects for long-term capital growth. Through the support of their experienced investment managers, innovation consultants, capital and networks, ALMI create opportunities for businesses to grow and compete in a global market. ALMI invest from the seed phase to the expansion phase and are located across the whole of Sweden, with regional knowledge and an international perspective. The ALMI portfolio consists of 400 growth companies in many different industries.
Almi Invest as well as ALMI Företagspartner are subsidiaries of the Almi Group.